000			04080nam a2200421 i 4500
988			_aSpringer_BiomedLife_2019
999			_c115803 _d115803 _x1
001			115803
003			ESmaUEC
005			20230110040238.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			190903s2019 gw | s |||| 0|eng d
020			_a9783030220051
024	7		_a10.1007/978-3-030-22005-1 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQP752 .B54 _b2019 EB
245	0	0	_aBile Acids and Their Receptors _cedited by Stefano Fiorucci, Eleonora Distrutti.
250			_a1st ed. 2019.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2019
300			_a1 recurso en línea (X, 378 páginas) _b 57 ilustraciones, 37 ilustraciones a color
336			_aTexto _btxt _2rdacontent
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aHandbook of Experimental Pharmacology _x0171-2004 _v256
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aPreface -- Part 1. Bile acids as signaling molecules and their receptors -- 1. A short history of bile acid pharmacology -- 2. Bile acids activated receptors: a review of GPBAR1 (TGR5) and other G-protein-coupled receptors -- 3. Bile acid activated receptors: a review of FXR and other Nuclear receptors -- 4. The intestinal enterokine fibroblast growth factor 15/19 in bile acid metabolism -- 5. Signaling from intestine to the host. How bile acids regulate intestinal and liver immunity -- Part 2. General pharmacology of bile acid activated receptors and their ligands -- 6. Modeling of bile acid activated receptors as a tool for pharmacological development -- 7. Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists and antagonists -- 8. Non steroidal FXR ligands: current status and clinical applications -- 9. Intestinal selective FXR agonists and their potential in treating liver and metabolic diseases -- Part 3. Bile acids and their derivatives as drugs -- 10. UDCA, Nor-UDCA and T-UDCA: a review of their mechanisms of action and clinical applications -- 11. Chenodeoxycholic acid: an update on its therapeutic appplications and safety profile -- 12. Obeticholic acid: a review of its mechanisms of action and clinical applications -- Part 4. Bile acid activated receptors as therapeutic targets -- 13. Targeting FXR in cholestasis -- 14. FXR agonists for the treatment of NASH and other metabolic disorders -- 15. Targeting bile acids activated receptors in bariatric surgery.
520	3		_aThis book focusses on the latest results related to the field of bile acids as signaling molecules and describes how these receptors have become a major pharmacological target. It covers all major areas of research in this field, from genetics, chemistry, in silico modeling, molecular biology to clinical applications, offering a cross-country view of the functional role of bile acids as signaling molecules, virtually acting on all major areas of metabolism. While FXR and GPBAR1 are essential bile acid sensors that integrate the de novo bile acid synthesis with intestinal microbiota and liver metabolism, in a broader sense, BARs play a pathogenic role in the development of common human alignments including liver, intestinal and metabolic disorders, such as steatosis (NAFLD) and steato-hepatitis (NASH), diabetes, obesity and atherosclerosis. .
650		7	_2embne _aLípidos _9142933
700	1		_aFiorucci, Stefano _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aDistrutti, Eleonora _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030220044
776	0	8	_iPrinted edition: _z9783030220068
776	0	8	_iPrinted edition: _z9783030220075
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-22005-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b12/2019 _eIG _zSI